PMID- 34595427
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211002
IS  - 2590-0048 (Electronic)
IS  - 2590-0048 (Linking)
VI  - 1
IP  - 3
DP  - 2019 Sep
TI  - The Impact of First Complete Remission by PET-CT and Time to Next Treatment on 
      Survival of Follicular Lymphoma Patients.
PG  - 168-172
LID - 10.2991/chi.d.190528.001 [doi]
AB  - We retrospectively analyzed the impact of initial positron emission tomography 
      and computed tomography (PET-CT) complete remission (CR) and time to next 
      treatment (TTNT) on patient outcome in follicular lymphoma. Between 2002 and 
      2014, 150 patients could be evaluated for treatment response and long-term 
      outcome. The CR after first line treatment with either 
      rituximab-cyclophosphamide, oncovin, and prednisolone (R-COP) or 
      rituximab-cyclophosphamide, doxorubicin, oncovin, and prednisolone (R-CHOP) was 
      89% and partial response (PR) was 7%. The 5- and 10-year survival rates were 
      86.0% and 62.6%, respectively. In five years, 11% of patients had died of 
      lymphoma and 3% from other causes. Forty-seven patients (31%) underwent a second 
      line of treatment comprising 19 (40%) with a TTNT shorter than 24 months and 28 
      (60%) longer than 24 months. There was no difference in overall survival (OS) 
      between R-COP (86%) and R-CHOP (77%) at 5 years, but there were more next 
      treatment events in the R-COP compared with the R-CHOP group on longer follow-up 
      (60% versus 35% at 8 years). For PET-CT response, there was a significant OS 
      difference between initial CR and PR patients (88% versus 70%, p < 0.01), and a 
      longer TTNT was seen in initial CR patients. Patients with a TTNT longer than 24 
      months had better OS compared with patients with a shorter TTNT (93% versus 54% 
      at 5 years, p < 0.01). In conclusion, patients with initial PET-CT CR and TTNT 
      longer than 24 months had better OS compared with those achieving only PR and 
      shorter TTNT. PET-CT CR should be considered the treatment goal during initial 
      treatment, and more aggressive treatment should be considered for patients with a 
      TTNT of less than 24 months.
CI  - (c) 2019 International Academy for Clinical Hematology. Publishing services by 
      Atlantis Press International B.V.
FAU - Tan, Tran-Der
AU  - Tan TD
AD  - Hematology and Medical Oncology, Koo Foundtion Sun Yat-Sen Cancer Center, No 125, 
      Li-Teh Road, Bei-Tou district, Taipei, Taiwan, ROC.
FAU - Chiou, Lun-Wei
AU  - Chiou LW
AD  - Hematology and Medical Oncology, Koo Foundtion Sun Yat-Sen Cancer Center, No 125, 
      Li-Teh Road, Bei-Tou district, Taipei, Taiwan, ROC.
FAU - Wu, Mau-Ching
AU  - Wu MC
AD  - Hematology and Medical Oncology, Koo Foundtion Sun Yat-Sen Cancer Center, No 125, 
      Li-Teh Road, Bei-Tou district, Taipei, Taiwan, ROC.
FAU - Wu, Jia-Shing
AU  - Wu JS
AD  - Radiation Oncology, Koo Foundtion Sun Yat-Sen Cancer Center, No 125, Li-Teh Road, 
      Bei-Tou district, Taipei, Taiwan, ROC.
FAU - Lee, Ming-Yuan
AU  - Lee MY
AD  - Pathology, Koo Foundtion Sun Yat-Sen Cancer Center, No 125, Li-Teh Road, Bei-Tou 
      district, Taipei, Taiwan, ROC.
FAU - Huang, Yu-Yi
AU  - Huang YY
AD  - Nuclear Medicine, Koo Foundtion Sun Yat-Sen Cancer Center, No 125, Li-Teh Road, 
      Bei-Tou district, Taipei, Taiwan, ROC.
FAU - Chen, Shing-Su
AU  - Chen SS
AD  - Radiology, Koo Foundtion Sun Yat-Sen Cancer Center, No 125, Li-Teh Road, Bei-Tou 
      district, Taipei, Taiwan, ROC.
LA  - eng
PT  - Journal Article
DEP - 20190901
PL  - England
TA  - Clin Hematol Int
JT  - Clinical hematology international
JID - 101759455
PMC - PMC8432364
OTO - NOTNLM
OT  - Follicular lymphoma
OT  - PET-CT response
OT  - Time to next treatment (TTNT)
COIS- The authors have no other affiliations or financial involvement with any 
      organization or entity apart from those disclosed. The authors have no financial 
      interest in or financial conflict with the subject matter or materials discussed 
      in the manuscript.
EDAT- 2019/09/01 00:00
MHDA- 2019/09/01 00:01
PMCR- 2019/09/01
CRDT- 2021/10/01 07:39
PHST- 2019/02/13 00:00 [received]
PHST- 2019/05/14 00:00 [accepted]
PHST- 2021/10/01 07:39 [entrez]
PHST- 2019/09/01 00:00 [pubmed]
PHST- 2019/09/01 00:01 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - CHI-1-3-168 [pii]
AID - 10.2991/chi.d.190528.001 [doi]
PST - epublish
SO  - Clin Hematol Int. 2019 Sep 1;1(3):168-172. doi: 10.2991/chi.d.190528.001. 
      eCollection 2019 Sep.